Filing Flows › Health Care › Vivos Therapeutics (VVOS)
Vivos Therapeutics (VVOS) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 14, 2026 · Vivos Therapeutics (VVOS) Q2 2026 earnings results →
Q2 2026 Revenue up 35% year over year to $5.2M · 107¢ of every $1 of revenue lost · operating margin -93.6%
Vivos Therapeutics made $5.2M in Q2 2026 (+35% Y/Y): Service $3.8M, Product $1.4M. Operating margin -93.6%, net loss $5.5M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 14, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $5.2M in Q2 2026, up 35% year over year and roughly flat from the previous quarter. Sleep Testing Services was the largest line at 46% of revenue. Sleep Testing Services added $1.5M year over year (up 183%), 116% of the total change. VIP declined 91%.
Gross margin was 57.3%, up 2.1 points from Q2 2025. Operating costs exceeded revenue by $4.8M, an operating margin of -93.6%. Operating expenses grew 12% against revenue growth of 35%. The fastest-growing cost line was Other operating costs (+67%). The quarter ended with a net loss of $5.5M, narrower than the previous quarter's $7.8M loss. Minority interests bore $42K of it: to shareholders the quarter was a loss of $5.5M.
Operating cash flow was −$3.1M. Non-cash charges added back $510K of depreciation and amortization and $50K of share-based compensation. Working capital and other items added $1.8M. Capital expenditures of $416K exceeded it, leaving free cash flow of −$3.6M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 14, 2026 | $5.2M | +35% | -93.6% | −$5.5M | −$3.1M |
| Q1 2026 | 10-Q | May 20, 2026 | $5.1M | +70% | -128.7% | −$7.8M | −$6.0M |
| Q4 2025 | 10-K | Apr 15, 2026 | $3.8M | +3% | -166.9% | −$6.9M | −$3.8M |
| Q3 2025 | 10-Q | Nov 19, 2025 | $6.8M | +76% | -69.8% | −$5.4M | −$4.2M |
| Q2 2025 | 10-Q | Aug 19, 2025 | $3.8M | -6% | -127.4% | −$5.0M | −$3.5M |
| Q1 2025 | 10-Q | May 15, 2025 | $3.0M | -12% | -129.9% | −$3.9M | −$3.8M |
| Q4 2024 | 10-K | Mar 31, 2025 | $3.7M | +14% | -75.9% | −$2.8M | −$2.9M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Vivos Therapeutics
We are a revenue stage medical technology and healthcare services company that features a comprehensive suite of proprietary oral appliances and therapeutic treatments. Our products non-surgically treat certain maxillofacial and developmental abnormalities of the mouth and jaws that are closely associated with breathing and sleep disorders such as mild to severe obstructive sleep apnea (known as OSA) and snoring in adults. We call the use of our appliances coupled with specific therapeutic treatment protocols The Vivos Method. The Vivos Method is estimated to be indicated and potentially effective (within the scope of the FDA cleared uses) in approximately 80% of cases of OSA where patients are compliant with clinical treatments. Our patented C.A.R.E. oral appliances have been utilized in approximately 60,000 patients treated worldwide by more than 2,000 trained dentists.
In its own words, from its 10-K, filed Apr 15, 2026.
Vivos Therapeutics against its Surgical & Medical Instruments & Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +35% against the peers' median +5%. Operating margin: -93.6% against the peers' median 13.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| VVOS Vivos Therapeutics | Q2 2026 | $5.2M | +35% | -93.6% |
| MDLN Medline | Q3 2026 | $7.9B | +10% | 6.4% |
| MMM 3M | Q3 2026 | $6.6B | +1% | 23.7% |
| SYK Stryker | Q3 2026 | $6.5B | +8% | 15.9% |
| BSX Boston Scientific | Q3 2026 | $5.1B | +1% | 16.1% |
| BDX Becton Dickinson | Q3 FY26 | $5.0B | +5% | 13.3% |
| BAX Baxter International | Q3 2026 | $3.0B | +5% | 7.6% |
| SOLV Solventum | Q3 2026 | $1.9B | -7% | 3.5% |
| RMD ResMed | Q1 FY27 | $1.4B | +6% | 32.0% |
Source: Vivos Therapeutics 10-Q on SEC EDGAR · CIK 1716166 · Surgical & Medical Instruments & Apparatus
13F: who owns VVOS and who is buying
More on VVOS
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results